Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. (DRMA) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · DRMA · as of Mar 31, 2025
Ownership Breakdown
8
Institutional Holders
▲ 2 vs Q4
$561,194
Total Inst. Value
▲ $499,729 vs Q4
681,557
Shares Outstanding
freeFloat 73.15%
518,513
13F Shares Held
▲ 472,984 vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
DRMA largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 8 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ARMISTICE CAPITAL, LLC pharmaceutical preparations | 411.0K | 7.97% | 7.97% | $443.88M | May 15, 2025 | ▲ 383.8K |
UBS GROUP AG pharmaceutical preparations | 70.3K | 1.36% | 1.36% | $75.91M | May 13, 2025 | ▲ 56.4K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 20.4K | 39.58% | 39.58% | $22.04M | May 13, 2025 | NEW |
JONES FINANCIAL COMPANIES LLLP pharmaceutical preparations | 12.0K | 23.28% | 23.28% | $14.16M | May 28, 2025 | NEW |
WELLS FARGO & COMPANY/MN pharmaceutical preparations | 2.0K | 3.88% | 3.88% | $2.16M | May 13, 2025 | ▼ 45 |
TOWER RESEARCH CAPITAL LLC (TRC) pharmaceutical preparations | 1.8K | 3.48% | 3.48% | $1.94M | May 15, 2025 | ▲ 402 |
SBI SECURITIES CO., LTD. pharmaceutical preparations | 1.0K | 1.94% | 1.94% | $1.08M | May 2, 2025 | — held |
BANK OF AMERICA CORP /DE/ pharmaceutical preparations | 21 | 0.04% | 0.04% | $23,000 | May 15, 2025 | ▲ 5 |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
4
Increased
+440.6K shares2
New Positions
first time holders1
Decreased
−45 shares0
Sold Out
fully exitedNet shares change (top 50)
+440.6K
+440.6K / −45
Net new holders
+5
2 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
DRMA insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
19
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Bedoya-Toro Munera Maria E SVP, Regulatory Affairs | Feb 17, 2026 | Purchase | 1,000 | $1.27 | $1.3K | 1.0K | Form 4 ↗ |
PROEHL GERALD T President, CEO and Chairman | Jan 2, 2026 | Award | 37,500 | $2.18 | $81.8K | 37.5K | Form 4 ↗ |
HALE DAVID F director | Jan 2, 2026 | Award | 2,500 | $2.18 | $5.5K | 2.5K | Form 4 ↗ |
WIERENGA WENDELL director | Jan 2, 2026 | Award | 2,500 | $2.18 | $5.5K | 2.5K | Form 4 ↗ |
Bedoya-Toro Munera Maria E SVP, Regulatory Affairs | Jan 2, 2026 | Award | 9,000 | $2.18 | $19.6K | 9.0K | Form 4 ↗ |
Scott Kathleen D. director | Jan 2, 2026 | Award | 2,500 | $2.18 | $5.5K | 2.5K | Form 4 ↗ |
Nardo Christopher J. Senior VP, CDO | Jan 2, 2026 | Award | 18,000 | $2.18 | $39.2K | 18.0K | Form 4 ↗ |
Sandler Andrew Seth director | Jan 2, 2026 | Award | 2,500 | $2.18 | $5.5K | 2.5K | Form 4 ↗ |
Van Hoose Kyri K. SVP, CFO | Jan 2, 2026 | Award | 18,000 | $2.18 | $39.2K | 18.0K | Form 4 ↗ |
Mento Steven J director | Jan 2, 2026 | Award | 2,500 | $2.18 | $5.5K | 2.5K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Dermata Therapeutics, Inc. (DRMA) is primarily owned by institutional investors, who hold approximately 76.1% of total shares outstanding. Company insiders own approximately 26.85%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Dermata Therapeutics, Inc. is ARMISTICE CAPITAL, LLC, holding approximately 411,000 shares — equal to 7.97% of outstanding shares — as of March 31, 2025.
A total of 8 institutional investors currently hold DRMA stock, with a combined institutional value of approximately $561,194 as of the most recent 13F filing period.
Frequently asked questions
DRMA ownershipDermata Therapeutics, Inc. (DRMA) is primarily owned by institutional investors, who hold approximately 76.1% of shares. The largest shareholder is ARMISTICE CAPITAL, LLC with a 7.97% stake. Company insiders hold 26.85%. Data sourced from SEC Form 13F as of March 31, 2025.